Skip to main content

Table 1 Clinical characteristics of the patient cohort

From: Th17 expansion in granulomatosis with polyangiitis (Wegener's): the role of disease activity, immune regulation and therapy

Characteristic Remission Active disease
Number 42 18
Age, years, mean ± SD 58 ± 13 54 ± 14
PR3/MPO 37/5 11/7
Disease duration, months, mean ± SD 105 ± 75 67 ± 97
Treatment, yes/no 16/26 7/11
Steroids, yes/no 13/3 (12 patients: 5 to 10 mg; 1 patient: 30 mg) 7/0 (4 patients: 5 to 10 mg; to 45 mg)
AZA/MMF/MTX/CYC 7/2/4/0 2/1/0/0
  1. PR3/MPO, proteinase-3/myeloperoxidase (describes the anti-neutrophil-cytoplasmic antibodies specificity at the time of diagnosis); AZA, azathioprine; CYC, cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate.